Abstract
The significance of cyclooxygenase-2 (COX-2) expression in mesenchymal tumors has not been completely described. We analyzed clinicopathologic variables and COX-2 protein expression in all mesenchymal tumors of the GI tract that were treated at our institution between 1990 and 2002. Paraffinembedded specimens were immunohistochemically stained for KIT and COX-2 protein. KIT-positive tumors were diagnosed as gastrointestinal stromal tumors (GIST). Among 42 available specimens, 38 tumors were diagnosed as GIST and four were non-GIST mesenchymal GI tumors (KIT negative). The median overall survival for the GIST patients was 34 months. Ninety-two percent of GIST expressed COX-2 protein. COX-2 protein was not expressed in any of the non-GIST tumors. GIST patients with negative or low COX-2 expression developed disease recurrence and/or died of their disease in 37% of the cases, compared with 18% for GIST patients with high COX-2 expression (difference not statistically significant). The vast majority of mesenchymal tumors of the GI tract are GIST that express COX-2 protein. As opposed to known predictors of GIST behavior such as tumor size and mitotic count, levels of COX-2 protein expression did not correlate with clinical outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813–3825.
Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134–1142.
Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): A review. Eur J Cancer 2002;38(Suppl_5):S39-S51.
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–480.
Emile JF, Theou N, Tabone S, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004;2:597–605.
Suster S. Gastrointestinal stromal tumors. Semin Diagn Pathol 1996;13:297–313.
Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001;32:578–582.
DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–58.
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459–465.
Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients’ prognosis. World J Gastroenterol 2003;9:1990–1994.
Saukkonen K, Rintahaka J, Sivula A, et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003;111:915–925.
Yoshida S, Amano H, Hayashi I, et al. COX-2/VEGFdependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest 2003;83:1385–1394.
Leung WK, To KF, Go MY, et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 2003;23(5):1317–1322.
Okajima E, Uemura H, Ohnishi S, et al. Expression of cyclooxygenase- 2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection. Aktuelle Urol 2003;34:256–258.
Castilla EA, Prayson RA, Kanner AA, et al. Cyclooxygenase- 2 in oligodendroglial neoplasms. Cancer 2003;98:1465–1472.
Kim HS, Youm HR, Lee JS, Min KW, Chung JH, Park CS. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 2003;42:163–170.
Sutton KM, Wright M, Fondren G, Towle CA, Mankin HJ. Cyclooxygenase-2 expression in chondrosarcoma. Oncology 2004;66:275–280.
Sheehan KM, Sabah M, Cummins RJ, et al. Cyclooxygenase-2 expression in stromal tumors of the gastrointestinal tract. Hum Pathol 2003;34:1242–1246.
Jhala N, Jhala D. Gastrointestinal tract cytology: Advancing horizons. Adv Anat Pathol 2003;10:261–277.
Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.
Fujita T, Matsui M, Takaku K, et al. Size- and invasiondependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823–4826.
Sheehan KM, Sheahan K, O’Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254–1257.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stewart, A.E., Heslin, M.H., Arch, J. et al. Cyclooxygenase-2 expression and clinical outcome in gastrointestinal stromal tumors. J Gastrointest Surg 10, 315–319 (2006). https://doi.org/10.1016/j.gassur.2005.05.012
Issue Date:
DOI: https://doi.org/10.1016/j.gassur.2005.05.012